What are the indications for ivonib? What types of cancers and mutations does it apply to?

Ivosidenib is a targeted drug mainly used to treat certain types of cancer, especially tumors related to IDH1 gene mutations. IDH1 (isocitrate dehydrogenase 1) gene mutation is a common cancer-related mutation, especially in some blood cancers. The mechanism of action of ivonib is to inhibit the activity of IDH1 mutant enzyme, thereby blocking the metabolic pathways in tumor cells and slowing down the growth of cancer cells.

Ivonib is mainly used to treat acute myeloid leukemia (AML) associated with IDH1 gene mutations. In clinical trials, ivosidenib has been shown to have significant efficacy in treating this specific mutated type of AML. For those AML patients with IDH1 mutations, ivosidenib can help control tumor growth and improve patient survival by targeting this specific genetic mutation.

In addition, ivosidenib is also being studied for the treatment of other types of cancer, such as certain solid tumors, particularly cholangiocarcinoma. The incidence of IDH1 mutations is high in cholangiocarcinoma, and the efficacy of ivonib in these cancers has also been initially verified. Although not yet widely approved for other types of cancer, ivonib has shown promising therapeutic potential in targeting IDH1 mutations.
The efficacy and indications of ivonib are still being studied and expanded. With greater understanding of the role of IDH1 mutations in different cancer types, ivonib may be used to treat more tumors, especially those with cancers that have specific genetic mutations. Therefore, ivosidenib provides a new targeted treatment option for the treatment of certain types of cancer, especially for patients who have limited response to traditional treatments.
Reference link: https://www.tibsovo.com/